Solid Biosciences (SLDB) CFO logs RSU vesting and tax-related share sale

Rhea-AI Filing Summary

Solid Biosciences Inc. CFO & Treasurer Kevin Tan reported routine equity transactions. On January 9, 2026, 11,250 restricted stock units (RSUs) converted into the same number of common shares at an exercise price of $0.00, reflecting scheduled vesting. On January 13, 2026, he sold 5,704 shares of common stock at $5.27 per share.

According to the disclosure, this sale was made solely to cover withholding taxes under an automatic “sell-to-cover” instruction adopted on August 15, 2024, and is described as not a discretionary trade by Mr. Tan. After these transactions, he directly holds 46,100 shares of common stock and 11,250 RSUs, with RSUs converting to common stock on a one-for-one basis and vesting in four equal annual installments from January 9, 2023.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tan Kevin

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/09/2026		M		11,250	A	(1)	51,804(2)	D
Common Stock	01/13/2026		S		5,704(3)	D	$5.27	46,100(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/09/2026		M			11,250	(4)	(4)	Common Stock	11,250	$0.00	11,250	D

Explanation of Responses:

1. Restricted stock units convert to common stock on a one-for-one basis.

2. Includes 4,152 and 4,152 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 30, 2025 and November 28, 2025, respectively.

3. This sale was made to cover withholding taxes following the vesting of previously granted RSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Tan on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Tan.

4. The restricted stock units were granted on January 9, 2023 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

	/s/ Kimberly Cornwell as attorney-in-fact for Kevin Tan	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did SLDB CFO Kevin Tan report?

Kevin Tan reported the vesting and conversion of 11,250 restricted stock units into common stock on January 9, 2026, and the sale of 5,704 common shares on January 13, 2026.

How many Solid Biosciences (SLDB) shares did Kevin Tan sell and at what price?

On January 13, 2026, Kevin Tan sold 5,704 shares of Solid Biosciences common stock at $5.27 per share.

Why did Kevin Tan sell Solid Biosciences (SLDB) shares in January 2026?

The filing states the 5,704-share sale was made to cover withholding taxes after RSU vesting, under a durable automatic sale instruction letter adopted on August 15, 2024, and was not a discretionary trade.

What RSU activity did Kevin Tan report for Solid Biosciences (SLDB)?

On January 9, 2026, 11,250 restricted stock units converted into the same number of common shares at an exercise price of $0.00, consistent with the RSUs’ vesting schedule.

How many Solid Biosciences (SLDB) shares and RSUs does Kevin Tan hold after these transactions?

Following the reported transactions, Kevin Tan directly holds 46,100 shares of Solid Biosciences common stock and 11,250 restricted stock units.

What is the vesting schedule for Kevin Tan’s reported restricted stock units at SLDB?

The RSUs were granted on January 9, 2023 and vest over four years, with 25% of the original number of shares vesting on each anniversary of the grant date until the fourth anniversary.